A Registry Trial of The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 785 participants.

Also called NCT04179045

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 785 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04179045
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04179045. Allocation not applicable; no masking; primary purpose treatment. Start 2021-03-01 (anticipated); primary completion 2022-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Registry Trial of The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System
Intervention (Device)
The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System
Lead sponsor
Shanghai Bio-heart Biological Technology Co., Ltd. (class: industry)
Collaborator
CCRF Inc., Beijing, China (class: industry)

Record details

Record id
cardio:ct-nct04179045
Content hash
16d740ecccfc1b87df54a86c536a13ef58c3523df2115559aa545985f9ad9bb8